Stocks scoring 0–25 beat the S&P 500
39.9% of the time over the next three months, since 2015.
How we measured this →
9
hedge funds
hold it · 1 new, 1 added, 6 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$8.1B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About RHYTHM PHARMACEUTICALS INC
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity,…
Who's behind the signal
Every informed buyer we can see on RYTM, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
RHYTHM PHARMACEUTICALS INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
1
New positions
1
Increasing
6
Decreasing
1
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to RHYTHM PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell RHYTHM PHARMACEUTICALS INC or any security.